Browsing Tag
ViiV Healthcare
13 posts
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
GSK reshapes ViiV Healthcare ownership as Shionogi replaces Pfizer with $2.1bn investment
Pfizer exits ViiV Healthcare as Shionogi boosts its stake to 21.7%. Find out how GSK is reshaping HIV strategy with a streamlined ownership structure.
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
GSK Q1 2025 earnings: Specialty medicines power growth as pipeline builds investor confidence
GSK's Q1 2025 earnings beat forecasts on strong Specialty Medicines growth and pipeline strength—read full results, investor sentiment, and stock outlook.
EC approves Cabotegravir LA by ViiV Healthcare for HIV prevention
ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC)…
Strides Pharma’s HIV generic drug gets tentative FDA approval
Strides Pharma Science Limited (Strides) announced that its Singapore-based stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited,…
Aurobindo Pharma gets tentative FDA approval for generic HIV treatment for children
Aurobindo Pharma Limited has achieved a significant milestone by securing the US Food and Drug Administration (FDA)’s tentative…
Lupin gains tentative FDA approval for Dolutegravir Tablets generic
Indian pharmaceutical company Lupin announced that the US Food and Drug Administration (FDA) has granted tentative approval for…
ViiV Healthcare’s Cabenuva secures FDA approval for HIV treatment
ViiV Healthcare has received FDA approval for Cabenuva, a long-acting treatment regimen for HIV-1 infection in adult patients.…